Abstract
Although the aetiology of MS remains elusive, several genetic approaches have provided clues to the underlying molecular pathogensis. In addition to the well known association to HLA class II alleles, weak but highly significant association to the interleukin-7 receptor and interleukin-2 receptor genes has recently been established. A series of other promising candidate genes identified in large genome screens are under evaluation. The genetic predisposition to MS is so far shown to be mediated by common polymorphisms in genes encoding molecules involved in T cell activation and homeostasis, but only a small proportion of the potential susceptibility genes have yet been identified. Analyses of transcribed immune receptor genes have revealed evidence of antigen-driven clonal expansion of lymphocytes, and may also provide tools for charting their specificites. Recently, attempts to identify disease-associated genes through transcriptional profiling have revealed new candidate players in MS pathogenesis. Whereas genetic studies in humans may identifiy individual molecular players, transgenic animal models allow detailed examination of molecular pathways. These studies have shown that in addition to altered protein function, alteration of gene expression may contribute to disease development. We here review how different genetic approaches can be combined to elucidate the immunopathogenesis of MS.
Current Molecular Medicine
Title: Genetic and Molecular Approaches to the Immunopathogenesis of Multiple Sclerosis: An Update
Volume: 9 Issue: 5
Author(s): Trygve Holmoy, Hanne Harbo, Frode Vartdal and Anne Spurkland
Affiliation:
Abstract: Although the aetiology of MS remains elusive, several genetic approaches have provided clues to the underlying molecular pathogensis. In addition to the well known association to HLA class II alleles, weak but highly significant association to the interleukin-7 receptor and interleukin-2 receptor genes has recently been established. A series of other promising candidate genes identified in large genome screens are under evaluation. The genetic predisposition to MS is so far shown to be mediated by common polymorphisms in genes encoding molecules involved in T cell activation and homeostasis, but only a small proportion of the potential susceptibility genes have yet been identified. Analyses of transcribed immune receptor genes have revealed evidence of antigen-driven clonal expansion of lymphocytes, and may also provide tools for charting their specificites. Recently, attempts to identify disease-associated genes through transcriptional profiling have revealed new candidate players in MS pathogenesis. Whereas genetic studies in humans may identifiy individual molecular players, transgenic animal models allow detailed examination of molecular pathways. These studies have shown that in addition to altered protein function, alteration of gene expression may contribute to disease development. We here review how different genetic approaches can be combined to elucidate the immunopathogenesis of MS.
Export Options
About this article
Cite this article as:
Holmoy Trygve, Harbo Hanne, Vartdal Frode and Spurkland Anne, Genetic and Molecular Approaches to the Immunopathogenesis of Multiple Sclerosis: An Update, Current Molecular Medicine 2009; 9(5) . https://dx.doi.org/10.2174/156652409788488793
DOI https://dx.doi.org/10.2174/156652409788488793 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Enzymes Metabolizing Aristolochic Acid and their Contribution to the Development of Aristolochic Acid Nephropathy and Urothelial Cancer
Current Drug Metabolism Endoradiotherapy with Peptides - Status and Future Development
Current Medicinal Chemistry Floating Drug Delivery Systems for Prolonging Gastric Residence Time: A Review
Current Drug Delivery Targeting the Immune System in Cancer
Current Pharmaceutical Biotechnology Obesity and Arterial Compliance Alterations
Current Vascular Pharmacology Targeted Delivery of Anti-Inflammatory Agents to Tumors
Current Pharmaceutical Design Clinical Impacts of Juxtapapillary Duodenal Diverticulum Detected on Computed Tomography
Current Medical Imaging Porphyrins as Radiosensitizing Agents for Solid Neoplasms
Current Pharmaceutical Design Effect of Administration Route on the Biodistribution and Shedding of Replication-Deficient AAV2: A Qualitative Modelling Approach
Current Gene Therapy From Nanotechnology to Nanomedicine: Applications to Cancer Research
Current Molecular Medicine Engineered Nanoparticles for Improved Vasoactive Intestinal Peptide (VIP) Biomedical Applications
Recent Patents on Nanomedicine Current Perspective of Natural Alkaloid Carbazole and its Derivatives as Antitumor Agents
Anti-Cancer Agents in Medicinal Chemistry Adhesion Dependent Signalling in the Tumour Microenvironment: The Future of Drug Targetting
Current Pharmaceutical Design Patent Selections:
Recent Patents on Biomarkers Short-Term Intra-Nasal Erythropoietin Administration with Low Sialic Acid Content is without Toxicity or Erythropoietic Effects
Current Neurovascular Research Advances in Photodynamic Therapy of Cancer
Current Cancer Therapy Reviews Roles of Epithelial-Mesenchymal Transition in Cancer Drug Resistance
Current Cancer Drug Targets Development of Cisplatin Nanoparticles as Dry Powder Inhalers for Lung Cancer
Current Nanoscience The Metabolic Syndrome and HIV Infection
Current Pharmaceutical Design Ascorbic Acid in Cancer Chemoprevention: Translational Perspectives and Efficacy
Current Drug Targets